Quality standards for DNA sequence variation databases to improve clinical management under development in Australia  by Bennetts, B. et al.
Applied & Translational Genomics 3 (2014) 54–57
Contents lists available at ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atgQuality standards for DNA sequence variation databases to improve
clinical management under development in AustraliaB. Bennetts a, M. Caramins b, A. Hsu c, C. Lau d, S. Mead e, C. Meldrum f, T.D. Smith c,i,⁎, G. Suthers g,h, G.R. Taylor c,
R.G.H. Cotton c,i, V. Tyrrell d
a Western Sydney Genetics Program, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia
b SDS Pathology, North Ryde, NSW 2113, Australia
c Genomic Medicine, Department of Pathology, University of Melbourne, Melbourne, VIC 3010, Australia
d Royal College of Pathologists of Australasia, 207 Albion Street, Surry Hills, NSW 2010, Australia
e South Eastern Sydney Laboratory Services, Prince of Wales Hospital, Randwick, NSW 2031, Australia
f Hunter Area Pathology Service, John Hunter Hospital, New Lambton Heights, NSW 2305, Australia
g SA Clinical Genetics Service, SA Pathology, Adelaide, SA 5000, Australia
h Department of Paediatrics, University of Adelaide, SA 5008, Australia
i Human Variome Project International, Level 5, 234 Queensberry Street, University of Melbourne, VIC 3010, Australia⁎ Corresponding author at: Level 5, 234 Queensberry S
VIC 3010, Australia. Tel.: +61 3 8344 2096.
E-mail address: tim@variome.org (T.D. Smith).
http://dx.doi.org/10.1016/j.atg.2014.07.002
2212-0661/© 2014 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 16 April 2014
Received in revised form 30 June 2014





Global knowledge sharingDespite the routine nature of comparing sequence variations identiﬁedduring clinical testing to database records,
few databases meet quality requirements for clinical diagnostics. To address this issue, The Royal College of
Pathologists of Australasia (RCPA) in collaboration with the Human Genetics Society of Australasia (HGSA),
and the Human Variome Project (HVP) is developing standards for DNA sequence variation databases intended
for use in the Australian clinical environment. The outputs of this project will be promoted to other health
systems and accreditation bodies by the Human Variome Project to support the development of similar
frameworks in other jurisdictions.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
It has now become routine practice to compare sequence variations
identiﬁed during clinical genetic testing with variants recorded in a
wide range of genetic variation databases as well as in the scientiﬁc
literature to aid in understanding the potential clinical signiﬁcance
and determining a deﬁnitive diagnosis. Although numerous genetic
variation databases already exist, there are few that meet the accuracy
and reproducibility required for clinical diagnostics. Current databases
are of variable quality and many contain errors in variant calls, non-
standardized nomenclature, incomplete pathogenicity associations
and limited phenotypic information linked to genomic data (Saunders
et al., 2012). These all represent limitations and risks to the quality of
patient care. Based on the current research experience of highly curated
mutation data (Thompson et al., 2014; Sosnay et al., 2013) the curation
of databases to clinical standards is likely to require a substantial invest-
ment of time and effort.treet, University of Melbourne,
. This is an open access article underThe increasing ease of access to technologies such as massively par-
allel sequencing is producing increasing volumes of genomic data that
needs to be recorded in an organized, accurate manner. The integrity
of this stored data is critical as there becomes a greater demand for
analysis and interpretation in clinical research and diagnostics, a task
which now forms a substantial proportion of the genetic diagnostic
workload.
There are numerous initiatives and white papers, which discuss the
steps needed to allow for responsible integration of emerging genomic
technologies into mainstream clinical diagnostics, many of which
touch on data quality and collection. Some of these are described below.
Data to Discovery: Genomes to Health (Ahalt et al., 2014) made
recommendations on data provenance, collection, and management;
delineation of phenotypes; adjudication of genomic variants; biostatis-
tics and bioinformatics, data sharing; and bioethics and the law.
The Global Alliance for Genomics and Health has established data,
security, regulatory and ethics, and clinical working groups who have
established priorities which include the development of formal data
models, application programming interface (API) implementations for
submitting, exchanging, querying, and analyzing genomic data (Global
Alliance for Genomics and Health, 2014).
The British Society for Genetic Medicine made public the outcomes
of the BSGM 100,000 Genome Group which made recommendationsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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and policies, promotion of data sharing, and further development
of the existing NHS Diagnostic Mutation Database (DMuDB) and
DECIPHER database to be more readily usable for the clinical laboratory
(Burn and Douglas, 2013). This was followed up by reports on recom-
mendations from the United Kingdom appointed working groups
(https://www.gov.uk/government/publications/mapping-100000-
genomes-strategic-priorities-data-and-ethics).
Recent challenges being addressed by the eMERGE network and
others include collection of phenotype data, the integration of genomic
ﬁndings into electronic health records, and the current efforts to extend
HL7 Version 2 vocabularies for exome and whole genome sequencing
within the context of clinical workﬂows (Kullo et al., 2014; Chute
et al., 2013).
In September 2013, the National Human Genome Research Institute
(NHGRI) and the Eunice Kennedy Shriver National Institute of Child
Health and Development (NICHD) awarded USD25M to support a
consortium of three groups to design and implement a framework for
evaluating variants, and their role in patient care. This consortium is
enabling access to this information through the NCBI ClinVar database.
The International Collaboration for Clinical Genomics (ICCG) is a part
of this project, and is intended to support data collection and sharing
(http://www.iccg.org/about-the-iccg/clingen/).
In addition to the white papers and initiatives, there is a growing
number of best practice policies and guidelines addressing the responsi-
ble integration of genomics into a clinical environment such as those
released by the Association for Clinical Genetic Science (ACGS, part of
the British Society of Genetic Medicine (BSGM)) and the Dutch Society
of Clinical Genetic Laboratory Specialists (VKGL) (Wallis et al., 2013),
American College of Medical Genetics and Genomics (ACMG) (Rehm
et al., 2013), the Clinical Molecular Genetics Society, UK (CMGS), also
part of the British Society of Genetic Medicine (BSGM) (Ellard et al.,
2012), Best Practice Guidelines for the use of Next-Generation Sequenc-
ing Applications in Genome Diagnostics from a National Collaborative
Study of Dutch Genome Diagnostic Laboratories (Weiss et al., 2013), a
draft NIH Genomic Data Sharing Policy (Draft NIH Genomic Data
Sharing Policy — Request for Public Comments, 2013), and conclusions
from a working group of experts in genomic research, analysis and
clinical diagnostic sequencing convened by the NHGRI (MacArthur
et al., 2014). All of these guidelines partially address data within the
clinical genomics workﬂow, however they do not focus speciﬁcally on
the area.
Collection of information related to genetic variation is not a new
concept, with over 2000 locus speciﬁc databases established with
disease and/or gene speciﬁc variation information. There are currently
no established ISO standards which govern sequence variation data-
bases. There are however numerous de-facto standards and established
best practices (Vihinen et al., 2012).While this aids with providing con-
sistent formats, they are in part outdated as genomic data becomes
more readily accessible and available. With regard to guidelines for
the establishment of locus speciﬁc databases (LSDBs), the Human
Variome Project (HVP) has been collaboratingwith theHumanGenome
Variation Society, and the GEN2PHEN project, working towards stan-
dardizing the way that variation and pathogenicity data is presented.
In addition Celli et al. developed a supporting document describing
curation of a gene variant database as ﬁrst step to establishing guide-
lines for database curation (Celli et al., 2012). The HVP continues to
promote global standards and guidelines which encourage the estab-
lishment and maintenance of quality-assured sequence variation data
repositories. Their ongoing work is described further below.
2. The standards development project
Despite the initiatives and guidelines described above, there are no
speciﬁc standards or equivalent mechanisms which concentrate on
guiding the accreditation of DNA sequence variation databases toensure the accuracy, quality, and ongoing maintenance of uploaded
data into any central repository to meet the needs of the clinical diag-
nostics environment.
An Australian national project led by the Royal College of Patholo-
gists of Australasia (RCPA) in collaboration with the Human Genetics
Society of Australasia (HGSA) and the Human Variome Project (HVP)
is developing standards for DNA sequence variation databases intended
for use in the clinical environment. This project is being supported by
theAustralianDepartment of Health's Quality Use of Pathology Program
(QUPP).
The standards under developmentwill be a broad reaching set of na-
tional standards that are sympathetic to the rapidly changing landscape
of genomics in the clinic to seek compliance by both existing and future
databases. The fundamental principle of the document is to provide a
standard for oversight for DNA sequence variation databases intended
to provide utility in clinical diagnostic service delivery, and thereby
ensure that they are developed, curated, andmaintained as safe, secure,
and accurate repositories of genomic data. They are intended to comple-
ment existing laboratory standards and accreditation requirements,
align with global initiatives and guidelines in existence, act as a guide
to identify a quality database, establish new databases as well as
improve existing databases that have evolved out of the research envi-
ronment, and set minimum requirements for clinical purposes within
the boundaries of existing legislation both nationally and globally.
3. The standards framework
The framework within which the standards are being developed
consists of nine key areas described in Table 1. The framework is
intended to adequately address the accreditation requirements in a sys-
tematic orderwith clearly deﬁned and concise criteria. In each section of
the document, points deemed important for practice will be identiﬁed
as either ‘Standards’ or ‘Guidelines’ in the style of current National Pa-
thology Accreditation Advisory Council (NPAAC) documents (National
Pathology Accreditation Advisory Council (NPAAC), 2008). A Standard
will be considered the minimum requirement for a procedure, method,
stafﬁng resource or laboratory facility that is required before a laborato-
ry can attain accreditation. A Guideline will be a consensus recommen-
dation for best practice and should be used if a higher level of practice is
appropriate. A Commentarymay also be provided to give clariﬁcation to
the Standards and Guidelines as well as to provide examples and
guidance on interpretation of the statements.
4. Implementation of the standards
Accreditation of pathology laboratories for clinical service delivery in
Australia is overseen by the National Pathology Accreditation Advisory
Council (NPAAC). NPAAC is an agency within the Commonwealth
(Federal) Department of Health. NPAAC plays a key role in ensuring
the quality of Australian pathology services, and is responsible for the
development andmaintenance of standards and guidelines for patholo-
gy practices (http://www.health.gov.au/npaac). The National Associa-
tion of Testing Authorities (NATA) is the authority which provides
independent assurance of technical competence in conjunction
with the Royal College of Pathologists of Australasia (RCPA) through a
proven network of best practice industry experts. NATA/RCPA provides
assessment, accreditation, and training services to laboratories
and technical facilities throughout Australia and internationally
(http://www.nata.asn.au). NATA audits against the standards and
guidelines laid down by NPAAC. Laboratories seeking eligibility for
Federal government funding for medical tests are required to meet the
speciﬁed quality standards as expressed by NPAAC in the context of
the Australian pathology accreditation framework. There are a number
of specialized technical publications that specify requirements in labo-
ratories undertaking speciﬁc areas of medical testing in addition to re-
quirements for good medical practice in all pathology laboratories.
Table 1
Framework for development of standards for DNA sequence variation databases.
Framework areas Items being considered in each of the areas (include, but not limited to)
Purpose • Scope of the database
• Nature of information being held in the database
• Quality parameters
• Standard operating procedures
Governance • Custodian deﬁnition, accountability, and responsibility
• Mechanisms for complaints, troubleshooting, auditing, and risk mitigation
• Ethics committee, advisory board, and multidisciplinary team involvement
• Sustainability, and contingency in case of demise
• Compliance with jurisdictional legislations and or regulations
Establishment • Principle hardware and software requirements including web interfacing, networking, infrastructure, storage, backup capabilities
• Compatibility — external databases, electronic health/medical records (EMR/EHR), HL7 V2, SNOMED-CT, federated databases.
Protection privacy security • Content of an information policy (such as how data are collected, used, disclosed, managed, administered, stored, and accessed)
• Compliance with local Australian (Privacy Amendment Act 2012) and other jurisdictional legislation/regulation such as HIPAA.
• Consent for storage of data, and use of data for diagnostic and or research purposes
• Privacy, security through de-identiﬁcation, data encryption, and protected access
• Security breach management
Content • Data to be collected and submitted including but not limited to data structure, nomenclature and variant description, methodology
used to detect the variant, orthogonal method veriﬁcation, sequence quality data, reference genome, provenance of existing data,
variant occurrences, inheritance information, phenotype, and clinical accreditation status of submitting laboratories.
Functionality • Version control, modiﬁcations
• Interrogation and return of information from external databases, linkage of variant occurrences and familial grouping
• Mechanisms to track de-identiﬁed data to facilitate patient management.
Currency of information • Speciﬁc DNA database curation deﬁnition and requirements
• Filtering and triaging variant calls, determination of relevance and inclusion
• Quality controls and evaluation of level of conﬁdence in accuracy
• Maintaining relevance and accuracy of data,
• Maintaining currency of genome builds and compatibility of variants recorded
• Regular audits to assure quality of the database schema and data held within.
Access & sharing • Policy governing participation through access and sharing
• Mechanisms for facilitating access and sharing through secure practices
• User registration, and the clinical need to utilize the data
• Communication between user and curator/custodian
• Quality Control, auditing of access and sharing
Professional use • Standardizing ontology within a database, or between federated databases
• Variant classiﬁcation, traceability of clinical reports, re-analysis
• Skill sets, knowledge base, and experience required
• Workforce training and development
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are intended to be an adjunct to existing NPAAC standards and
guidelines such as “Requirements for Medical Pathology Services
(Requirements for Medical Pathology Services (First Edition, 2013);
National Pathology Accreditation Advisory Council (NPAAC), 2008)”
and “Requirements for the Retention of Laboratory Records and Diag-
nostic Material (Requirements for the Retention of Laboratory Records
and Diagnostic Material (Sixth Edition, 2013) National Pathology
Accreditation Advisory Council, 2013)”. When completed, the standards
will be submitted for potential endorsement by the RCPA and HGSA
boards, and will be made available as a tool for laboratories and NATA
assessors alike to facilitate accreditation. Further, the RCPA will engage
the NPAAC to seek their inclusion of these Standards in the Common-
wealth Health Insurance (Accredited Pathology Laboratories) —
Approval Principles 2002.
It is recognized that there is a need to bridge a gap between the
translational research environment and the clinical diagnostic environ-
ment, and therefore regulation of the use of data within the scope of the
respective environments. To address this, in addition to the NATA/RCPA
andNPAAC requirements, the Standardswill encourage users to comply
with the Australian Government National Health and Medical Research
Council National Statement on Ethical Conduct in Human Research
2007 (Updated March 2014) (National Statement on Ethical Conduct
in Human Research, 2007).
5. Challenges to implementation
There are foreseeable challenges to the implementation of a set of
standards such as those described above. Initial acceptance and imple-
mentation of a new set of standards can be difﬁcult to achieve withoutend users supporting the accreditation or compliance requirements.
Early communication of this initiative is underway, and includes broad
consultation with key experts and stakeholders who will be impacted
by the introduction of standards, and presentation of the standards in
draft form at local scientiﬁc meetings for discussion. It is the intention
of the project steering committee that the resulting set of standards
gains support prior to their ﬁnal release.
Further to this, to ensure the implementation of and compliance
with the standards, continued accreditation could be monitored via
the development by a professional organization of a time limited license
or registration program applied to the databases and operators of those
databases. Elements could include an external quality assessment
program and automated auditing or review of the elements, functions,
and curation of the databases. Online training and certiﬁcation of
database users under a continuing professional development (CPD) or
continuing medical education (CME) program could be implemented
to ensure the information held in databases is appropriately utilized in
a clinical environment.
Sequence variation databases are housed both locally and offshore in
multiple countries, with ownership existing outside of Australian
jurisdiction. It will be difﬁcult for laboratories to apply these standards
locally unless they “own” the database. However, the standards will
provide them with a tool to judge the integrity and therefore the level
of conﬁdence that they might apply to an overseas database, which in
turn can be included in their quality systems for future accreditation
of bioinformatic pipelines for analysis and interpretation.
This project is being undertakenwithin the context of the Australian
healthcare system and its national- and state-based legislation and
regulations governing the quality of medical services. However, given
the global reach of individual databases, the ﬁndings from this project
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frameworks, and perhaps more broadly. Sharing knowledge, experi-
ence, and aligning standards globally in a structured and coordinated
manner is critical to advancing the successful implementation of geno-
mics testing in the clinical environment.
6. Broader adoption and the global view
Gaining international consensus and commitment to consistent
standards in medical testing represents a major challenge. One mecha-
nism for achieving this outcome is theHumanVariomeProject, an inter-
national initiative to integrate the routine and responsible sharing
of genetic variation information into standard clinical practice. The
Human Variome Project is a consortium of researchers, diagnosticians
and health-care professionals committed to the free and open sharing
of genetic variation information generated during clinical testing, there-
by leading to better patient outcomes and more accessible genetic
health services. The Project is working towards establishing globally
acceptable Standards and Guidelines for the collection, curation, inter-
pretation and sharing of genomic knowledge and enabling the sustain-
able development and operation of a harmonized and federated global
knowledge sharing network. A key aspect of this work is harmonizing
national and regional efforts around regulatory frameworks and gover-
nance of electronic data repositories and knowledge sharing infrastruc-
ture. The Project, through its Variant Database Quality Assessment
Working Group has speciﬁed guidelines for quality parameters that
should be assessed in a quality accreditation scheme (in press).
In addition to The Human Variome Project global initiatives,
Australia is well represented in the Global Alliance for Genomics and
Health (http://www.genomicsandhealth.org), with Alliance partners
including the Human Variome Project, National Health and Medical
Research Council (NHMRC), Australian Genome Research Facility
(http://agrf.org.au), Garvan Institute of Medical Research, Melbourne
Genomics Health Alliance and other highly regarded groups (http://
genomicsandhealth.org/partners).
7. Conclusion
Regulating the quality, accuracy, and relevance of DNA sequence
variation databases and the data held within them through the imple-
mentation of standardswill reduce the risk of aberrant or uninformative
variants being reported, promote the sharing of clinical quality sequenc-
ing, and accelerate the delivery of accurate, actionable, and efﬁcient
clinical reports to improve patient management and outcomes. The
Australian standards development reported above will build on work
undertaken to date, and is a promising step towards national and
regional harmonization efforts. We hope that the outcome of this
project will be of interest to other countries and health systems.
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